Newsletter 17/2010
15
October 2010
[gs]
evotec OR
morphoSys? google OR gene-sensor? time OR sly stone? or: why it pays
to use gene-sensor! If you do not
wish to receive this newsletter anymore, just reply to this mail
without any comment and you will be taken off the mailing list.
-----------------------------
Dear reader:
as probably all of you are aware
there is hardly any industry that is developing more rapidly than the
life sciences industry! New companies, collaborations, new products,
acquisitions make the daily news.
However,
gene-sensor.com is the perfect tool for any business person who wants
to keep track of this sea change in a very comfortable and affordable,
yet powerful way.
We worked hard to make it as easy as possible to use [gs] and this
Newsletter will present an example, that simply uses the word
»OR«, in capital letters, to do so – just
like google does.Example
Search for German Biotechs – evotec OR
morphosys
Two of the most prominent and
probably most successful German biotech companies are Evotec AG, a drug
discovery services company headquartered in Hamburg, and MorphoSys, an
antibody company headquarted in the Munich region, somehow a little bit
outside of Germany, in Bavaria.
Both companies have a long history
with a lot of acquisitions and collaborations. Now, just ask yourself
what you know about those two players and then go on and ask google and
[gs]!
_______
Ask
google about Evotec and MorphoSys
The result
at google : About 326.000 results (0,23
seconds)
Search Results
Evotec
is a leader in the discovery and development of novel small molecule
drugs.
Evotec
is a leader in the discovery and development of novel small molecule
drugs. The Company has substantial drug discovery expertise and an
...
www.evotec .com/articles/en/Careers/8
- Cached
[LIST CONTINUES ...]
_______
Ask
gene-sensor.com about Evotec and MorphoSyshttp://www.gene-sensor.com/index.php?script=3000&str=evotec+OR+morphosys
Global Search › Result
Search term »evotec OR
morphosys«
Now, let us face the numbers:
We at [iito] Business Intelligence actually have to admit that the
»Server processing time:
8.291479 seconds«
at gene-sensor.com is about eight horrible seconds longer than the
google search, that took slightly above 0.2 seconds.
However, we have firm reason to believe that you very quickly will
recover the time lost by directly accessing the structured content
using [gs].
For example, let us take a look at the first 100 of the 235
collaborations!
Almirall–Evotec:
drug discovery services, 201009– collab €na
identification of small-molecule ion channel modulators for respiratory
diseases 2010-09-23
Roche–Evotec:
drug discovery services, 201005– collab €na service
discovery small molecule drugs for Genentech 2010-05-10
Evotec–Hypha
Discovery: MycoDiverse natural compound library, 201003–
supply access to Hypha’s MycoDiverse collection for Evotec
for lead generation 2010-03-18
Active
Biotech–Evotec: drug discovery services, 201003–
service €na identification of small molecule leads by HT
screening for specific target 2010-03-11
Boehringer–Evotec:
drug discovery services, 200911– collab research + license
extension + expansion 4y to incl oncology targets 2009-11-09
Biogen
Idec–Evotec: drug discovery services, 200909–
collab service €na drug screening and lead discovery 2009-09-09
Evotec–De
Facto Communications: public relations, –200909–
service existent 2009-09-09
Alios–Evotec:
high-troughput screening, 200907– collab service €na
uHTS priority biological target for Alios w access to Evotec small
molece library 2009-07-21
Cubist–Evotec:
fragment-based drug discovery, 200907– resarch agreem use of
EVOlution for small molecule + fragments screening 2009-07-14
Concateno–MorphoSys:
diagnostic antibodies, 200907– supply €na two
antibodies by AbD Serotec for clinical diagnostic kits of Spinreact SA 2009-07-09
Grupo
Ferrer–Evotec: chemical compound libraries, 200907–
service 2y extension synthesis + purification by Evotec-RSIL for
screening by Ferrer 2009-07-07
Evotec–Promega:
HaloTag technology, 200905 supply use existent by Evotec in drug
screening 2009-05-27
Boehringer–DeveloGen:
metabolic disease drugs, 200905– asset sale + collab
€7m upfront + €237m milestones + royalties + research
funding 2009-05-13
Evotec–Summit:
zebrafish screening technology, 200905 acquisition of zebrafish
screening operations €500k in cash
SEE
Summit–Evotec:
investment, 200905 acquisition of zebrafish screening operations
€500k in cash
2009-05-07
Academy
of Sciences (AT)–Evotec: drug discovery + development,
200904– collab IMBA with European ScreeningPort 2009-04-28
Roche–Evotec:
drug discovery services, 200903– collab development alliance 2009-03-01
Novartis–Evotec:
drug discovery, 200812–201111 collab service 3y
identification + developm small molecule therapeutics 2008-12-03
Galapagos–Morphosys:
therapeutic antibodies, 200811– collab co-developm in bone +
joint disease w profit + cost sharing 2008-11-26
MorphoSys–Wacker:
ESETEC technology, 200811– license expansion right to use
prokaryotic secretion technology 2008-11-18
NEU²
project–Evotec: MS drug RnD, 200809– collab
European Screening Port GmbH is project member 2008-09-30
NEU²
project–Evotec: MS drug RnD, 200809– collab Evotec
AG is project member 2008-09-30
Morphosys–e2v
technologies: Biosensor System, 200809– collab research to
establish e2v's Visucare™ w AbD Serotec's HuCAL 2008-09-23
Evotec–ChemBioNet
project: chemical libraries, 200807– collab ChemBioNet with
European ScreeningPort 2008-07-28
Evotec–Greiner:
microplates, 200807– collab + supply to European
ScreeningPort to optimise screening process 2008-07-28
Astellas–MorphoSys:
RapMAT technology, 200807– license €na exercise of
pre-existing option under HuCAL collab 2008-07-23
Phadia–MorphoSys:
HuCAL-based antibodies, 200807– license implementation in
autoimmune tests Varelisa™ + EliA™ €na 2008-07-17
Boehringer–MorphoSys:
RapMAT technology, 200807– license option excercised
extending exist technol transfer €na 2008-07-09
Direvo
Biotech–Evotec: protein engineering technology,
200807– acquisition of Evotec patents previously licensed by
Direvo 2008-07-09
Schering-Plough–MorphoSys:
HuCAL Gold®, 200805– license €na 1y
extension for use of HuCAL Gold library at research site in Palo Alto 2008-05-19
Ono
Pharmaceutical–Evotec: drug discovery services,
200803– service up to 3y using EVOlution fragment-based drug
discovery technology 2008-03-27
MorphoSys–Crucell:
PER.C6® cell line, 200803– license €na for
use in production of MOR202 therap cancer antibody programme 2008-03-17
Spermatech–Evotec:
drug discovery services, 200803– service HTS + lead discovery
for small molecule male contraceptive 2008-03-12
InterMune–Evotec:
drug discovery services, 200803– service expansion medicinal
chemistry 2008-03-06
Progenika–MorphoSys:
HuCAL GOLD research antibodies, 200803– supply €na
to Proteomika SL by AbD Serotec 2008-03-05
Astellas–MorphoSys:
HuCAL® technology, 200803–201203 license extension
€na access to HuCAL Gold library at Astellas research site in
Tsukuba 2008-03-01
Sigma-Aldrich–MorphoSys:
HuCAL GOLD research antibodies, 200802– collab developm +
license for marketing via online sales platforms 2008-02-27
CHDI–Evotec:
drug discovery services, 200802–201012 collab service
extension up to $37m strategic partnering development
Huntington’s disease drugs 2008-02-14
United
States (govt)–MorphoSys: research antibodies,
–200801– supply NIDDK is existent customer of
AbDSerotec 2008-01-09
GeneFrontier–MorphoSys:
HuCAL® technology, 200712– collab expansion
€na programme offering J research orgs access to HuCAL mABs
against commerc rights 2007-12-10
Novartis–MorphoSys:
HuCAL technology, 200711– collab 10y $600m + milestones long
term alliance discovery HuCAL-based antibody therapeutics 2007-12-02
MorphoSys–Dyax:
antibody technology, 200711– license €na to phage
display + other patents incl sublicense right tog w MorphoSys technology 2007-11-20
Evotec–St
John's Mercy Medical Center: EVT201, –200710 collab phase2
study w pos top-line results executed in Sleep Medicine + Research
Center 2007-10-16
Genesis
Research–MorphoSys: therapeutic antibodies, 200710–
collab research €na w Genesis using HuCAL-based antibodies of
AdB Serotec 2007-10-08
DIL–Evotec:
compound libraries, 200707– collab jv established in India
design + synthesis + management as service 2007-07-11
Teva–DeveloGen:
PKB technology, 200706– license excl ww for treatment of
cancer by CureGenics Ltd 2007-06-19
Evotec–MerLion:
Fragment-Based Drug Discovery, 200706 acqu selected assets NMR
screening from Combinature + access to SAR-by-NMR™ 2007-06-13
MorphoSys–PVPE:
Imperacer™ assay technology, 200705– collab
extension ww co-marketing Imperacer™ + AbD MAbs by each
partner Chimera Biotec 2007-05-03
Astellas–MorphoSys:
HuCAL® technology, 200703–200802 license access to
HuCAL Gold library at Astellas research site in Tsukuba 2007-03-28
Boehringer–Evotec:
drug discovery services, 200703– collab €na multi-y
drug target discovery for Alzheimer treatments 2007-03-19
Interprotein
Corp–Evotec: drug development services, 200702–
collab service developm orally active IL-6 inhibitors for treatm of
inflammatory diseases 2007-02-28
GeneFrontier–MorphoSys:
HuCAL® technology, 200701– collab €na
strategic marketing in J expansion 2007-01-25
InterMune–Evotec:
drug discovery services, 200701c– service HTS using
EVOlution™ discovery platform 2007-01-01
Pfizer–MorphoSys:
HuCAL GOLD library, 200612–201112 collab extension RnD
therapeutic antibodies 2006-12-20
Hokkaido
Univ–MorphoSys: HuCAL Gold library,
–200612– supply existent customer of AbD Serotec 2006-12-04
Burnham
Institute–MorphoSys: HuCAL GOLD library, 200611–
collab €na research access to HuCAL research Abs for target
discovery 2006-11-28
Boehringer–MorphoSys:
HuCAL Gold, 200611– collab €na expansion exercise
option excl license for optimisation of therapeutic cancer antibody 2006-11-13
Daiichi
Sankyo–Evotec: drug discovery services, 200610–
service medical chemistry + compound profiling for Daiichi
Pharmaceutical Co Ltd 2006-10-16
United
States (govt)–MorphoSys: research antibodies,
200609– supply €na research Abs against 5
bacterial-derived toxins to USAMRIID AbD Serotec 2006-09-25
Evotec–ChemAxon:
cheminformatics, 200609– license ww complete product line
JChem platform 2006-09-05
Olympus–Evotec:
single molecule detection technology, 200607– acqu core
technology + transfer or license of related IP from Evotec Technologies
GmbH 2006-07-24
Genextra–Evotec:
small-molecule cancer drugs, 200607– collab RnD 2y + license
development drugs targeting HSP90 DAC 2006-07-18
Griffith
Univ–Evotec: Opera™ system, 200606 supply
installation of an Opera system at Eskitis Institute of Griffith Univ 2006-06-28
Novartis–MorphoSys:
HuCAL technology, 200606–201105 collab strategic expansion
HuCAL Gold® 2006-06-23
Roche–Evotec:
CNS drugs, 200606– collab discover + develop compounds
against target for CNS diseases + other indications 2006-06-21
OncoMed
Pharmaceuticals–MorphoSys: HuCAL® GOLD,
200606– access to HuCAL for 2y €na for RnD of
therapeutic antibodies for cancers 2006-06-08
Schering-Plough–MorphoSys:
HuCAL Gold®, 200605– license €na 2y for use
of HuCAL Gold library at research site in Palo Alto 2006-05-17
MorphoSys–Kazusa
DNA Research Institute: research antibodies,
–200605– collab existent development + distribution 2006-05-15
Daiichi
Sankyo–Evotec: drug discovery services, 200604–
service assay developm + screening for small molecule drug discovery
Sankyo Co Ltd 2006-04-27
Evotec–Volks-
und Raiffeisenbanken (D): financial services, 200604 offering
€18.5m new shares with DZ Bank AG as sole lead manager + sole
bookrunner 2006-04-26
Roche–Evotec:
drug discovery services, 200604– collab service 2y extension
RnD lead candidates for Roche cancer targets 2006-04-25
Roche–Evotec:
drug discovery services, 200604– collab service further
extention 1y ww discovery chemistry agreem 2006-04-25
Univ
Cincinnati–Evotec: high-throughput screening,
200604– purchase HTS system $2.8m + collab Evotec Technologies 2006-04-04
MorphoSys–Volks-
und Raiffeisenbanken (D): financial services, 200603 service DZ Bank AG
co-lead manager for placing to institutional investors 2006-03-28
MorphoSys–WestLB:
financial services, 200603 service WestLB AG lead manager for placing
to institutional investors 2006-03-28
Daiichi
Sankyo–MorphoSys: HuCAL GOLD®, 200603–
license + collab 2y+3y €na access to HuCAL GOLD library Tokyo
site + collab developm therap antibodies 2006-03-16
CHDI–Evotec:
drug discovery services, 200603–200802 collab service
strategic partnering for developing drugs for Huntington’s
disease 2006-03-01
MorphoSys–PVPE:
Imperacer™ assay technology, 200602– collab ww
co-marketing of Imperacer™ w HuCAL® antibodies AbD +
Chimera Biotec 2006-02-20
Evotec–Apeiron:
pain drugs, 200602– collab RnD discovery + developm small
molecules w novel concept for pain relief 2006-02-14
Evotec–Fisher
Scientific: high-content screening, 200601– license + collab
€na Evotec Technologies + Cellomics Inc 2006-01-30
Serologicals–MorphoSys:
research antibodies, 200601– distribution ww 3y of
HuCAL®-based rec research antibodies by Chemicon International
Inc 2006-01-10
Evotec–Roche:
MAO-B inhibitors, 200601– license ww excl for two compounds
incl EVT 301 in developm for Alzheimer 2006-01-09
Boehringer–Evotec:
drug discovery services, 200601–200812 collab extension +
expansion effectively doubling programme size 2006-01-01
Bayer–MorphoSys:
HuCAL®, 200512– 5y extension HuCAL GOLD®
antibody library access for Bayer Pharmaceuticals Corp w up to 25 new
antibody programs 2005-12-14
Merck
(US)–MorphoSys: HuCAL technology, 200512– 5y
license for use of HuCAL GOLD® + AutoCAL™
technologies in human therap antibody RnD to Merck & Co 2005-12-14
MorphoSys–Wacker:
ESETEC® technology, 200511– right to use E. coli K12
expression system of Wacker Biotech GmbH for Fab production 2005-11-07
Boehringer–Evotec:
drug discovery services, 200511– collab extension into
fee-for-service agreem for uHTS screening 2005-11-03
MorphoSys–Lilly:
rec protein protein technology, 200509– cross license AME
Kauffman patents + HuCAL Gold €na as part of patent dispute
settlement 2005-09-23
Evotec–Genedata:
Genedata Screener®, 200509– collab integration of
Screener in high content + throughput technology of Evotec Technologies
(LT) 2005-09-13
Shionogi–MorphoSys:
HuCAL® technology, 200509–200808 license 3y access to
HuCAL® Gold antibody library 2005-09-08
Evotec–Scienamics:
consulting, –200508– listed on website as reference
partner 2005-08-31
Debio–DeveloGen:
PTR-262, 200508– collab ww excl developm + license Debiopharm
SA will develop PTR-262 for out-licensing for myaysthenia gravis (LT) 2005-08-16
Evotec–Northbank
Communications: public relations, –200508– service
existent for Evotec Technologies (LT) 2005-08-01
Almirall–Evotec:
chemical library synthesis, 200507– service synthesis +
supply of chemical compound libraries >€2.5m 2y (LT) 2005-07-21
ImmunoGen–MorphoSys:
HuCAL® technology, 200506–200605 license 1y HuCAL
GOLD® for internal target research programs (LT) 2005-06-01
Pfizer–Renovis:
VR1 antagonists, 200505– collab + license ww excl developm +
commercialisation small-molecule drugs (LT) 2005-05-31
Jerini–MorphoSys:
drug discovery services, 200504– collab co-marketing ww excl
J of services + products of JPT + Antibodies by Design (LT) 2005-04-18
Roche–Evotec:
drug discovery services, 200504– collab service extention 1y
ww discovery chemistry agreem 2005-04-13
Mitsubishi
Chemical–Evotec: drug discovery services, 200502–
collab service medicinal chemistry Mitsubishi Pharma Corp (LT) 2005-02-28
AnorMED–Evotec:
drug development services, 200502– collab service EVOdevelop
for chemical developm of AMD 3100 (LT) 2005-02-16
Boehringer–MorphoSys:
HuCAL Gold, 200502– license extension + expansion 2005-02-01
1 2
3
Even if you just take a look at the news, it is clearly structured
access with a very simple search:
Documents › Result
Search term »evotec OR
morphosys«
Total
search results: 832 | Ordered by Date (descending)
1 2 3
... 7
8 9
[LIST CONTINUES...]
Now, try this feat on google and count until 8!
Like Sly Stone sang:
»Time meets another minute
at last. Take your time.«
Best
ML
-----------------------------------------------------------------------------------
©2010 by
[iito] Business Intelligence As this
newsletter is a free service, available to anybody without a
contractual
agreement, the writer disclaims any liabilities and explicitly advises
you, not to use this information for your own business
decisions.
Marcus Lippold
Phone +49(0)-421-9889 173mlippold@iito.de www.gene-sensor.com
This
communication is confidential. If you are not the intended recipient,
you should not copy or disclose the message to anyone, but should
kindly
notify the sender and delete the message.
Date
